BeiGene is a global biotech company whose BTK inhibitor zanubrutinib (Brukinsa) was approved for the treatment of CLL / SLL in January, providing patients with another important therapy option. In addition, the Max Foundation is a charitable foundation that accelerates health equity and ensures access to modern therapies is available in poorer countries. Over the years, CLL Society has been a champion of both causes, advocating for patients to have improved treatment options and for making access to treatment available to all who need it.
To their enormous credit, they have teamed up to offer zanubrutinib at no cost to patients in 29 low- and middle-income countries. Learn more about this effort in the article, BeiGene, Max Foundation team up to provide free Brukinsa to CLL patients in 29 low-income countries.
It is encouraging to see efforts like this to ensure all those impacted by CLL / SLL worldwide have access to lifesaving therapies and the best possible care. Hopefully, we will see more similar alliances between pharmaceutical companies and patient organizations to improve access to care and health equity going forward.
